Cost-Effectiveness of a Ketoanalogue-supplemented Very Low-protein Diet in CKD.

IF 5.6
Povero Massimiliano, Simion Tatiana, Lorenzo Pradelli
{"title":"Cost-Effectiveness of a Ketoanalogue-supplemented Very Low-protein Diet in CKD.","authors":"Povero Massimiliano, Simion Tatiana, Lorenzo Pradelli","doi":"10.1093/ndt/gfaf123","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is a global health concern with significant economic implications, particularly in the management of end-stage renal disease, which often requires kidney replacement therapy such as dialysis or transplantation. The rising incidence of ESRD is expected to increase healthcare costs substantially by 2030. Dietary protein restriction is a cornerstone of managing CKD progression, and the use of ketoanalogues in very low-protein diets (VLPD) has shown promise in delaying dialysis initiation. This study evaluates the cost-effectiveness of a vegetarian ketoanalogue-supplemented VLPD (s-VLPD) compared to a low-protein diet (LPD) in patients with CKD stages 4 and 5 in Italy.</p><p><strong>Methods: </strong>A Markov model was developed to simulate the health outcomes and costs for patients with CKD stages 4 or 5, treated with either s-VLPD or LPD. The analysis was conducted from both the Italian National Healthcare Service (NHS) and societal perspectives. Healthcare costs considered were: ketoanalogue supplementation, dialysis, and diet monitoring. Overall survival and quality-adjusted life years (QALYs) were used as effectiveness outcomes. Sensitivity analyses, including deterministic and probabilistic approaches, assessed the robustness of the results.</p><p><strong>Results: </strong>The s-VLPD strategy led to improved survival (+0.60 years) and increased QALYs (+0.49) compared to LPD, along with cost savings of approximately €34 000 per patient from the NHS perspective. From the societal perspective, s-VLPD resulted in a cost saving of €59 147 per patient. Sensitivity analyses confirmed that s-VLPD remains a dominant strategy, demonstrating both clinical and economic advantages.</p><p><strong>Conclusion: </strong>s-VLPD is a cost-effective strategy for managing CKD stages 4 and 5, offering improved patient outcomes and significant cost savings. The findings support the integration of s-VLPD in routine clinical practice, helping delay dialysis initiation, reduce the financial burden on healthcare systems, and improve patient quality of life.</p>","PeriodicalId":520717,"journal":{"name":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ndt/gfaf123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic kidney disease (CKD) is a global health concern with significant economic implications, particularly in the management of end-stage renal disease, which often requires kidney replacement therapy such as dialysis or transplantation. The rising incidence of ESRD is expected to increase healthcare costs substantially by 2030. Dietary protein restriction is a cornerstone of managing CKD progression, and the use of ketoanalogues in very low-protein diets (VLPD) has shown promise in delaying dialysis initiation. This study evaluates the cost-effectiveness of a vegetarian ketoanalogue-supplemented VLPD (s-VLPD) compared to a low-protein diet (LPD) in patients with CKD stages 4 and 5 in Italy.

Methods: A Markov model was developed to simulate the health outcomes and costs for patients with CKD stages 4 or 5, treated with either s-VLPD or LPD. The analysis was conducted from both the Italian National Healthcare Service (NHS) and societal perspectives. Healthcare costs considered were: ketoanalogue supplementation, dialysis, and diet monitoring. Overall survival and quality-adjusted life years (QALYs) were used as effectiveness outcomes. Sensitivity analyses, including deterministic and probabilistic approaches, assessed the robustness of the results.

Results: The s-VLPD strategy led to improved survival (+0.60 years) and increased QALYs (+0.49) compared to LPD, along with cost savings of approximately €34 000 per patient from the NHS perspective. From the societal perspective, s-VLPD resulted in a cost saving of €59 147 per patient. Sensitivity analyses confirmed that s-VLPD remains a dominant strategy, demonstrating both clinical and economic advantages.

Conclusion: s-VLPD is a cost-effective strategy for managing CKD stages 4 and 5, offering improved patient outcomes and significant cost savings. The findings support the integration of s-VLPD in routine clinical practice, helping delay dialysis initiation, reduce the financial burden on healthcare systems, and improve patient quality of life.

酮症类似物补充极低蛋白饮食治疗慢性肾病的成本效益。
背景:慢性肾脏疾病(CKD)是一个全球性的健康问题,具有重要的经济意义,特别是在终末期肾脏疾病的管理中,这通常需要肾脏替代治疗,如透析或移植。预计到2030年,ESRD发病率的上升将大幅增加医疗费用。饮食蛋白质限制是控制CKD进展的基石,在极低蛋白饮食(VLPD)中使用酮类似物在延迟透析开始方面显示出希望。本研究评估了意大利CKD 4期和5期患者中素食酮类似物补充VLPD (s-VLPD)与低蛋白饮食(LPD)的成本效益。方法:建立一个马尔可夫模型来模拟CKD 4期或5期患者接受s-VLPD或LPD治疗的健康结果和成本。该分析是从意大利国家医疗保健服务(NHS)和社会角度进行的。考虑的医疗费用包括:类酮补充、透析和饮食监测。总生存期和质量调整生命年(QALYs)作为疗效指标。敏感性分析,包括确定性和概率方法,评估结果的稳健性。结果:与LPD相比,s-VLPD策略提高了生存率(+0.60年),增加了QALYs(+0.49年),同时从NHS的角度来看,每位患者节省了约34000欧元的成本。从社会角度来看,s-VLPD为每位患者节省了59147欧元的成本。敏感性分析证实,s-VLPD仍然是一种主导策略,显示出临床和经济优势。结论:s-VLPD是治疗CKD 4期和5期的成本效益策略,可改善患者预后并显著节省成本。研究结果支持s-VLPD在常规临床实践中的整合,有助于延迟透析开始,减轻医疗保健系统的经济负担,并改善患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信